A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Shigella flexneri 2a Infection
Open Access
- 15 February 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (4) , 2241-2247
- https://doi.org/10.4049/jimmunol.0803141
Abstract
The protective Ag of Shigella, the Gram-negative enteroinvasive bacterium causing bacillary dysentery, or shigellosis, is its O-specific polysaccharide (O-SP) domain of the LPS, the major bacterial surface component. As an alternative to the development of detoxified LPS-based conjugate vaccines, recent effort was put into the investigation of neoglycoproteins encompassing synthetic oligosaccharides mimicking the protective Ags of the O-SP. We previously reported that when coupled to tetanus toxoid via single point attachment, a synthetic pentadecasaccharide representing three biological repeating units of the O-SP of Shigella flexneri 2a (SF2a), one of the most common Shigella serotypes, elicits a better serum anti-LPS 2a Ab response in mice than shorter synthetic O-SP sequences. In this study, we show that the pentadecasaccharide-induced anti-LPS 2a Abs protect passively administered naive mice from Shigella infection. Therefore, this three repeating units sequence, which is recognized by anti-SF2a sera from infected patients, acts as a functional mimic of the native polysaccharide Ag. Analyses of parameters influencing immunogenicity revealed that an investigational SF2a vaccine displaying a pentadecasaccharide:tetanus toxoid molar loading of 14:1 triggers a high and sustained anti-LPS Ab response, without inducing anti-linker Ab, when administered four times at a dose corresponding to 1 μg of carbohydrate. In addition, the profile of the anti-LPS Ab response, dominated by IgG1 production (Th2-type response), mimics that observed in human upon natural SF2a infection. This synthetic carbohydrate-based conjugate may be a candidate for a SF2a vaccine.Keywords
This publication has 49 references indexed in Scilit:
- Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against Streptococcus pneumoniae Type 14Infection and Immunity, 2008
- Structures of synthetic O-antigen fragments from serotype 2aShigella flexneriin complex with a protective monoclonal antibodyProceedings of the National Academy of Sciences, 2008
- Saccharide/protein conjugate vaccines for Bordetella species: Preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugatesVaccine, 2008
- Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in miceProceedings of the National Academy of Sciences, 2007
- O-Specific polysaccharide conjugate vaccine-induced IgG antibodies prevent invasion of Shigella into Caco-2 cells and may be curativeProceedings of the National Academy of Sciences, 2007
- O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2aCarbohydrate Research, 2006
- A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and MicrobiologyPLoS Medicine, 2006
- The Immunogenicity of the Tumor‐Associated Antigen Lewisy May Be Suppressed by a Bifunctional Cross‐Linker Required for Coupling to a Carrier ProteinChemistry – A European Journal, 2004
- The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicityVaccine, 1997
- Immunity to Experimental Pneumococcal Infection with an Artificial Antigen Containing a Saccharide of Synthetic OriginScience, 1940